20Med Therapeutics

20Med Therapeutics is a biotechnology startup founded in 2011 and based in The Netherlands. The company is focused on developing innovative polymer nanoparticle technology for the efficient intracellular delivery of RNA and DNA-based therapeutics and vaccines. Its proprietary nanoparticles are designed with smart functions, enabling them to protect fragile payloads, facilitate transport, cellular uptake, and release active Oligonucleotide-based payloads into the cytoplasm of target cells. These nanoparticles are highly flexible in functionalization, making them applicable in a broad field of medical therapeutics.

With a strong emphasis on biotechnology, 20Med Therapeutics aims to revolutionize the landscape of medical therapeutics and vaccines by leveraging its advanced nanoparticle technology. Although details about the last investment and investors are not available at the moment, the company's innovative approach and potential to address critical medical needs make it an intriguing prospect for potential venture capital investors seeking opportunities in the biotechnology space.